https://aminowire.news/news/2026/11/2026-access-to-medicine-index-diabetes-glp-1/ Amino Wireen 2026-11-10T18:19:09.000Z Access Index: GLP-1s lead diabetes R&D as access lags https://aminowire.news/og/news/2026/11/2026-access-to-medicine-index-diabetes-glp-1-16x9.jpg https://aminowire.news/news/2026/11/pepgen-pgn-edodm1-freedom2-dm1-phase-2/ Amino Wireen 2026-11-10T14:16:49.000Z PepGen reports 46.5% splicing correction in DM1 trial https://aminowire.news/og/news/2026/11/pepgen-pgn-edodm1-freedom2-dm1-phase-2-16x9.jpg https://aminowire.news/news/2026/11/altimmune-pemvidutide-reclaim-alcohol-use-disorder-aasld-2026/ Amino Wireen 2026-11-10T13:57:32.000Z Altimmune's pemvidutide cut heavy drinking days in Phase 2 https://aminowire.news/og/news/2026/11/altimmune-pemvidutide-reclaim-alcohol-use-disorder-aasld-2026-16x9.jpg https://aminowire.news/news/2026/11/argenx-unnatural-products-macrocyclic-peptide-acquisition/ Amino Wireen 2026-11-10T13:57:32.000Z Argenx to buy macrocyclic peptide biotech Unnatural Products https://aminowire.news/og/news/2026/11/argenx-unnatural-products-macrocyclic-peptide-acquisition-16x9.jpg https://aminowire.news/news/2026/11/boehringer-survodutide-synchronize-cvot-aha-2026/ Amino Wireen 2026-11-09T20:08:23.000Z Survodutide meets CV safety bar in Phase 3 obesity trial https://aminowire.news/og/news/2026/11/boehringer-survodutide-synchronize-cvot-aha-2026-16x9.jpg https://aminowire.news/news/2026/11/fda-naion-warning-glp-1-receptor-agonists/ Amino Wireen 2026-11-09T16:13:54.000Z FDA adds NAION eye-risk warning to all GLP-1 labels https://aminowire.news/og/news/2026/11/fda-naion-warning-glp-1-receptor-agonists-16x9.jpg https://aminowire.news/news/2026/11/glp1-discontinuation-cardiovascular-events-italy/ Amino Wireen 2026-11-10T20:25:34.000Z Italian study links stopping GLP-1s to higher event risk https://aminowire.news/og/news/2026/11/glp1-discontinuation-cardiovascular-events-italy-16x9.jpg https://aminowire.news/news/2026/11/hims-hers-q3-2026-results/ Amino Wireen 2026-11-09T22:06:25.000Z Hims Q3 revenue rose 49% as it cuts 2026 profit guide https://aminowire.news/og/news/2026/11/hims-hers-q3-2026-results-16x9.jpg https://aminowire.news/news/2026/11/hims-peptides-plus-november-launch/ Amino Wireen 2026-11-10T00:13:03.000Z Hims says Peptides+ will launch later this month https://aminowire.news/og/news/2026/11/hims-peptides-plus-november-launch-16x9.jpg https://aminowire.news/news/2026/11/lilly-foundayo-orforglipron-attain-osa-phase-3/ Amino Wireen 2026-11-09T18:06:24.000Z Lilly's Foundayo cuts sleep apnea events in Phase 3 https://aminowire.news/og/news/2026/11/lilly-foundayo-orforglipron-attain-osa-phase-3-16x9.jpg https://aminowire.news/news/2026/11/merck-efinopegdutide-mash-phase-2b/ Amino Wireen 2026-11-09T22:06:25.000Z Merck's efinopegdutide meets Phase 2b MASH endpoint https://aminowire.news/og/news/2026/11/merck-efinopegdutide-mash-phase-2b-16x9.jpg https://aminowire.news/news/2026/11/retatrutide-transcend-ckd-registry-results/ Amino Wireen 2026-11-09T14:15:50.000Z Retatrutide kidney trial results posted: GFR flat, albumin down https://aminowire.news/og/news/2026/11/retatrutide-transcend-ckd-registry-results-16x9.jpg https://aminowire.news/news/2026/11/sandoz-owozy-semaglutide-brazil-launch/ Amino Wireen 2026-11-10T02:09:04.000Z Sandoz launches Owozy semaglutide in Brazil https://aminowire.news/og/news/2026/11/sandoz-owozy-semaglutide-brazil-launch-16x9.jpg https://aminowire.news/news/2026/11/trex-tirzepatide-resistance-exercise-lean-mass/ Amino Wireen 2026-11-10T22:25:53.000Z T-REx: resistance training limited lean-mass loss on tirzepatide https://aminowire.news/og/news/2026/11/trex-tirzepatide-resistance-exercise-lean-mass-16x9.jpg https://aminowire.news/news/2026/11/cameo-sema-semaglutide-hfpef-exercise-pawp/ Amino Wireen 2026-11-11T02:18:55.000Z CAMEO-SEMA: semaglutide lowered exercise filling pressure https://aminowire.news/og/news/2026/11/cameo-sema-semaglutide-hfpef-exercise-pawp-16x9.jpg https://aminowire.news/news/2026/11/jnj-icotyde-icotrokinra-iconic-psa-1-phase-3/ Amino Wireen 2026-11-09T12:13:46.000Z J&J's Icotyde meets Phase 3 goal in psoriatic arthritis https://aminowire.news/og/news/2026/11/jnj-icotyde-icotrokinra-iconic-psa-1-phase-3-16x9.jpg